Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE versus SUFLAVE.
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotic laxative; induces bowel cleansing by retaining water in the intestinal lumen via osmotic effects, increasing intraluminal pressure and stimulating peristalsis.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Oral: 3 packets (each containing 17.5g sodium sulfate, 3.13g potassium sulfate, and 1.6g magnesium sulfate) dissolved in water as a single dose, or as two doses: first packet in evening, second and third packets next morning. Route: oral. Frequency: single or split dose for colonoscopy preparation.
250 mg intravenously every 12 hours.
None Documented
None Documented
Not applicable as intact drug; component electrolytes have variable half-lives: sulfate ~12-24 hours; potassium and magnesium are actively regulated with redistribution half-lives of minutes to hours.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily renal: sulfate ions are excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative